Screener
Palvella Therapeutics PVLA Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,334 | $4,074 |
| General and administrative | 5,521 | 3,797 |
| Total operating expenses | 14,855 | 7,871 |
| Operating loss | (14,855) | (7,871) |
| Other (expense) income: | ||
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's total operating expenses?
- Palvella Therapeutics (PVLA) reported total operating expenses of $14.86M in Q1 2026.
- How has Palvella Therapeutics's total operating expenses changed year-over-year?
- Palvella Therapeutics's total operating expenses increased by 88.7% year-over-year, from $7.87M to $14.86M.
- What is the long-term trend for Palvella Therapeutics's total operating expenses?
- Over 2 years (2021 to 2025), Palvella Therapeutics's total operating expenses has grown at a -31.9% compound annual growth rate (CAGR), from $83.25M to $38.6M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Palvella Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude